Jeffrey Sherman Member of the Nominating and Governance Committee Jeffrey Sherman Larimar Therapeutics Appoints Dr. Jeffrey W. Sherman to its Board of Directors Read more about Larimar Therapeutics Appoints Dr. Jeffrey W. Sherman to its Board of Directors Larimar Therapeutics to Present at the Citi 18th Annual BioPharma Conference Read more about Larimar Therapeutics to Present at the Citi 18th Annual BioPharma Conference Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results Read more about Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results Samantha Semenkow, Ph.D. – Citi Samantha Semenkow, Ph.D. Citi Yatin Suneja – Guggenheim Securities Yatin Suneja Guggenheim Securities Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601’s Phase 2 Friedreich's Ataxia Trial and to Initiate Open Label Extension Trial Read more about Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601’s Phase 2 Friedreich's Ataxia Trial and to Initiate Open Label Extension Trial Larimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical Officer Read more about Larimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical Officer Larimar Therapeutics Set to Join Russell 3000® Index Read more about Larimar Therapeutics Set to Join Russell 3000® Index Larimar Therapeutics Reports Preliminary Top-line Data from Phase 2 Trial’s 25 mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreich’s Ataxia and First Quarter 2023 Financial Results Read more about Larimar Therapeutics Reports Preliminary Top-line Data from Phase 2 Trial’s 25 mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreich’s Ataxia and First Quarter 2023 Financial Results Pagination First page « First Previous page ‹ Previous Page 1 Current page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next › Last page Last » Subscribe to
Larimar Therapeutics Appoints Dr. Jeffrey W. Sherman to its Board of Directors Read more about Larimar Therapeutics Appoints Dr. Jeffrey W. Sherman to its Board of Directors
Larimar Therapeutics to Present at the Citi 18th Annual BioPharma Conference Read more about Larimar Therapeutics to Present at the Citi 18th Annual BioPharma Conference
Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results Read more about Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results
Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601’s Phase 2 Friedreich's Ataxia Trial and to Initiate Open Label Extension Trial Read more about Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601’s Phase 2 Friedreich's Ataxia Trial and to Initiate Open Label Extension Trial
Larimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical Officer Read more about Larimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical Officer
Larimar Therapeutics Set to Join Russell 3000® Index Read more about Larimar Therapeutics Set to Join Russell 3000® Index
Larimar Therapeutics Reports Preliminary Top-line Data from Phase 2 Trial’s 25 mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreich’s Ataxia and First Quarter 2023 Financial Results Read more about Larimar Therapeutics Reports Preliminary Top-line Data from Phase 2 Trial’s 25 mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreich’s Ataxia and First Quarter 2023 Financial Results